Jyosna Devi Ravula , Ramakrishna Nirogi , Manthan D. Janodia
{"title":"“对2010年至2020年美国fda批准的505(b)(2)药品的审查,强调知识产权和对重新配方和新组合的监管考虑”[Journal of Pharmaceutical Sciences/ 112卷,第8期,2023年8月/ 2146-2175页]的更正。","authors":"Jyosna Devi Ravula , Ramakrishna Nirogi , Manthan D. Janodia","doi":"10.1016/j.xphs.2025.103716","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":16741,"journal":{"name":"Journal of pharmaceutical sciences","volume":"114 4","pages":"Article 103716"},"PeriodicalIF":3.7000,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Corrigendum to “Review on 505(b)(2) Drug products approved by USFDA from 2010 to 2020 emphasizing intellectual property and regulatory considerations for reformulations and new combinations” [Journal of Pharmaceutical Sciences/ Volume 112, Issue 8, August 2023/ Pages 2146-2175]\",\"authors\":\"Jyosna Devi Ravula , Ramakrishna Nirogi , Manthan D. Janodia\",\"doi\":\"10.1016/j.xphs.2025.103716\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":16741,\"journal\":{\"name\":\"Journal of pharmaceutical sciences\",\"volume\":\"114 4\",\"pages\":\"Article 103716\"},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2025-03-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of pharmaceutical sciences\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0022354925001741\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of pharmaceutical sciences","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0022354925001741","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
Corrigendum to “Review on 505(b)(2) Drug products approved by USFDA from 2010 to 2020 emphasizing intellectual property and regulatory considerations for reformulations and new combinations” [Journal of Pharmaceutical Sciences/ Volume 112, Issue 8, August 2023/ Pages 2146-2175]
期刊介绍:
The Journal of Pharmaceutical Sciences will publish original research papers, original research notes, invited topical reviews (including Minireviews), and editorial commentary and news. The area of focus shall be concepts in basic pharmaceutical science and such topics as chemical processing of pharmaceuticals, including crystallization, lyophilization, chemical stability of drugs, pharmacokinetics, biopharmaceutics, pharmacodynamics, pro-drug developments, metabolic disposition of bioactive agents, dosage form design, protein-peptide chemistry and biotechnology specifically as these relate to pharmaceutical technology, and targeted drug delivery.